View Future GrowthMach7 Technologies 과거 순이익 실적과거 기준 점검 0/6Mach7 Technologies 의 수입은 연평균 -4.9%의 비율로 감소해 온 반면, Healthcare Services 산업은 연평균 20.5%의 비율로 증가했습니다. 매출은 연평균 9.9%의 비율로 증가해 왔습니다.핵심 정보-4.85%순이익 성장률-3.12%주당순이익(EPS) 성장률Healthcare Services 산업 성장률1.72%매출 성장률9.88%자기자본이익률-25.89%순이익률-33.94%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트공시 • Apr 21Mach7 Technologies Limited to Report Q3, 2026 Results on Apr 24, 2026Mach7 Technologies Limited announced that they will report Q3, 2026 results at 4:12 PM, AUS Eastern Standard Time on Apr 24, 2026공시 • Jan 22Mach7 Technologies Limited to Report Q2, 2026 Results on Jan 30, 2026Mach7 Technologies Limited announced that they will report Q2, 2026 results on Jan 30, 2026공시 • Oct 23Mach7 Technologies Limited to Report Q1, 2026 Results on Oct 31, 2025Mach7 Technologies Limited announced that they will report Q1, 2026 results on Oct 31, 2025공시 • Aug 08Mach7 Technologies Limited to Report Fiscal Year 2025 Results on Aug 27, 2025Mach7 Technologies Limited announced that they will report fiscal year 2025 results on Aug 27, 2025공시 • Apr 14Mach7 Technologies Limited to Report Q3, 2025 Results on Apr 29, 2025Mach7 Technologies Limited announced that they will report Q3, 2025 results on Apr 29, 2025공시 • Jan 31Mach7 Technologies Limited to Report First Half, 2025 Results on Feb 27, 2025Mach7 Technologies Limited announced that they will report first half, 2025 results on Feb 27, 2025모든 업데이트 보기Recent updates공시 • Apr 21Mach7 Technologies Limited to Report Q3, 2026 Results on Apr 24, 2026Mach7 Technologies Limited announced that they will report Q3, 2026 results at 4:12 PM, AUS Eastern Standard Time on Apr 24, 2026공시 • Jan 22Mach7 Technologies Limited to Report Q2, 2026 Results on Jan 30, 2026Mach7 Technologies Limited announced that they will report Q2, 2026 results on Jan 30, 2026공시 • Oct 23Mach7 Technologies Limited to Report Q1, 2026 Results on Oct 31, 2025Mach7 Technologies Limited announced that they will report Q1, 2026 results on Oct 31, 2025공시 • Oct 02Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2025Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2025.공시 • Aug 08Mach7 Technologies Limited to Report Fiscal Year 2025 Results on Aug 27, 2025Mach7 Technologies Limited announced that they will report fiscal year 2025 results on Aug 27, 2025공시 • Jul 10+ 1 more updateMach7 Technologies Limited Provides Preliminary Unaudited Earnings Guidance for the Year Ended June 30, 2025Mach7 Technologies Limited provides preliminary unaudited earnings guidance for the year ended June 30, 2025. For the period, revenue is expected to finalize at approximately AUD 33 million to AUD 34 million in line with fiscal year 2025 guidance for revenue growth of 15-25% (AUD 33 million to AUD 36 million). This reflected strong growth in recurring revenue of approximately 20%. Contracted Annual Recurring Revenue is expected to finalize at approximately AUD 30 million to AUD 31 million, slightly below fiscal year 2025 guidance for CARR growth of 15-25% (AUD 32 million to AUD 35 million). OPEX growth will be less than revenue growth in line with fiscal year 2025 guidance.공시 • Apr 14Mach7 Technologies Limited to Report Q3, 2025 Results on Apr 29, 2025Mach7 Technologies Limited announced that they will report Q3, 2025 results on Apr 29, 2025공시 • Feb 28Mach7 Technologies Announces Product Launch of the Eunity Diagnostic Image Viewer Using Aws HealthimagingMach7 Technologies announced a breakthrough in medical imaging access, performance, and cloud enablement with the release of its eUnity Enterprise Diagnostic Viewer, which uses AWS HealthImaging. The release marks a major milestone for Mach7 in its continuing goal of delivering new, impactful offerings to the Healthcare IT sector. Mach7 is a part of the AWS Partner Network (APN), a global community that leverages programs, expertise, and resources to build, market, and sell customer offerings with smart integration to the cloud. The release is a significant innovation with advanced cloud capabilities that allow clinicians to have fast access to patient studies across the healthcare enterprise regardless of acquisition or data source. Key benefits: One visualization experience with the eUnity Zero Footprint Diagnostic Enterprise Viewer; Leverage High-Throughput JPEG 2000 (HTJ2K) utilized with AWS HealthImaging data stores; Federation of multiple archive locations including local storage and multiple AWS HealthImaging data stores. At petabyte scale, data transfer speeds equal to or exceeding traditional local storage models at petabyte scale, using AWS HealthImaging; Allows full control of data to support customized workflows, clinical research, and artificial intelligence (AI) modeling; The ability to segment studies for various reading groups and practices and build privilege-based access strategies for different user groups; Utilize current reading worklist to leverage current IT investments; All images are available from local or cloud data stores with no sacrifice in performance with full diagnostic image quality at sub-second latency. eUnity, using AWS HealthImaging, creates a powerful diagnostic imaging solution for clinicians and IT staff that enables automated, efficient workflows, vast scalability, and cost savings.공시 • Jan 31Mach7 Technologies Limited to Report First Half, 2025 Results on Feb 27, 2025Mach7 Technologies Limited announced that they will report first half, 2025 results on Feb 27, 2025공시 • Jan 30Mach7 Technologies Limited (ASX:M7T) announces an Equity Buyback for 24,124,104 shares, representing 10% for AUD 5 million.Mach7 Technologies Limited (ASX:M7T) announces a share repurchase program. Under the program, the company will repurchase up to 24,124,104 shares, representing 10% of its issued share capital, for AUD 5 million. The shares will be repurchased at the price no more than 5% above the volume weighted average price of company's shares over the five trading days prior to purchase. The shares repurchased will be cancelled. The program is valid till February 3, 2026. As of January 30, 2025, there are 241,241,047 outstanding shares.공시 • Jan 21Mach7 Technologies Limited to Report Q2, 2025 Results on Jan 31, 2025Mach7 Technologies Limited announced that they will report Q2, 2025 results on Jan 31, 2025공시 • Nov 12Mach7 Technologies Introduces UnityVue, A Next-Generation Radiology Reading Solution with Groundbreaking CapabilitiesMach7 Technologies announced the formal launch of UnityVue, a landmark radiology software platform developed in partnership with NewVue. UnityVue is a pioneering solution which integrates Mach7's well-renown eUnity Enterprise Diagnostic Viewer (eUnity) with NewVue's revolutionary EmpowerSuite Workflow Orchestrator, delivering a comprehensive software platform designed to improve radiology reading workflows. UnityVue consolidates radiology workflows by seamlessly integrating image viewing and worklist management. This cloud-based solution offers radiologists a powerful platform for task prioritization, AI-driven data aggregation, and enhanced diagnostic workflow—all from a single interface. UnityVue's ability to dynamically curate worklists and automate data normalization enhances productivity while reducing administrative burden. UnityVue's key features include cloud-based image access, real-time AI-driven workflow orchestration, automated data normalization, and a unified interface for radiologists to perform their tasks efficiently. With its zero-footprint design, UnityVue allows radiologists to access critical information from any location, enhancing productivity while reducing administrative complexity. Through the launch of UnityVue, Mach7 customers have a future proof, all-in-one solution that not only meets the current demands of radiologists but also anticipates future needs. By solving these critical challenges, healthcare organizations can deploy a platform that enhances job satisfaction for radiologists, improves patient care, and drives better business outcomes. Key Benefits: For Independent Delivery Networks: Unifying PACS: Integrates multiple PACS systems into a single platform, simplifying workflows and reducing inefficiencies. Gradual Cloud Migration: IDNs can migrate to the cloud incrementally, preserving existing systems while modernizing infrastructure. Disaster Recovery: Cloud-based continuity ensures radiologists can continue working during local system outages. Reduced IT Complexity: The zero-footprint design eliminates on-site server requirements and minimizes maintenance.공시 • Oct 11Mach7 Technologies Limited to Report Q1, 2025 Results on Oct 31, 2024Mach7 Technologies Limited announced that they will report Q1, 2025 results on Oct 31, 2024공시 • Oct 03Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2024Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2024.공시 • Jul 12Mach7 Technologies Limited to Report Fiscal Year 2024 Results on Aug 28, 2024Mach7 Technologies Limited announced that they will report fiscal year 2024 results on Aug 28, 2024공시 • Jul 10Mach7 Technologies Limited to Report Q4, 2024 Results on Jul 30, 2024Mach7 Technologies Limited announced that they will report Q4, 2024 results on Jul 30, 2024공시 • Apr 08Mach7 Technologies Limited to Report Q3, 2024 Results on Apr 24, 2024Mach7 Technologies Limited announced that they will report Q3, 2024 results on Apr 24, 2024공시 • Feb 15Mach7 Technologies Limited to Report First Half, 2024 Results on Feb 29, 2024Mach7 Technologies Limited announced that they will report first half, 2024 results on Feb 29, 2024공시 • Jan 23Mach7 Technologies Limited to Report Q2, 2024 Results on Jan 31, 2024Mach7 Technologies Limited announced that they will report Q2, 2024 results on Jan 31, 2024공시 • Nov 18Mach7 Technologies Limited Appoints Rebecca Thompson as DirectorMach7 Technologies Limited announced appointment of Rebecca Thompson as director. Date of appointment is 16 November 2023.공시 • Oct 23Mach7 Technologies Limited to Report Q1, 2024 Results on Oct 31, 2023Mach7 Technologies Limited announced that they will report Q1, 2024 results on Oct 31, 2023공시 • Sep 22Mach7 Technologies Limited Announces Board Changes, Effective 16 November 2023Mach7 Technologies Limited announced that Mr. Philippe Houssiau will retire as Non-Executive Director of the company, effective from the close of the Company's Annual General Meeting on 16 November 2023 and that Ms. Rebecca Thompson has agreed to join the Mach7 Board as an independent Non-Executive Director, following the conclusion of the Company's Annual General Meeting on 16 November 2023. Mr. Houssiau joined the Mach7 Board in January 2021 as an independent Non-Executive Director and has served on the Company's Remuneration and Nomination Committee. As a part of the recently announced Board renewal process Ms Thompson will be joining the Board as a Non-Executive Director. Ms Thompson has deep experience in financial markets with senior roles at global investment banks, most recently at J.P. Morgan, and with listed companies over her 30-year career to date. Since mid-2022 and until her recent appointment as head of investor relations at CSR Limited, Rebecca was a consultant to Mach7. Apart from providing Rebecca with a strong understanding of the Mach7 business and its market dynamics, the relationship has demonstrated Rebecca's professionalism, commercial acumen, compatibility and sound judgement. Rebecca's professional experience spans the property, resources, fintech and charitable sectors with a strong focus on sustainability and ESG. She holds a Bachelor Degree in Economics from the University of Sydney and has a graduate qualification in finance and investment.공시 • Aug 28Mach7 Technologies Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Mach7 Technologies Limited announced that they will report fiscal year 2023 results on Aug 31, 2023공시 • Aug 11Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023.공시 • Jul 28Mach7 Technologies Limited to Report Q4, 2023 Results on Jul 31, 2023Mach7 Technologies Limited announced that they will report Q4, 2023 results on Jul 31, 2023공시 • Feb 01Mach7 Technologies Limited Announces Change of Company SecretaryMach7 Technologies Limited announced the appointment of Mr. Tony Panther as Company Secretary, effective 1 February 2023, to replace Ms. Veronique Morgan-Smith, following team reassignments at Vistra Australia, the Company's provider of secretarial and corporate compliance services. Mr. Panther is a Chartered Accountant with over 30 years' experience in a variety of fields. Following completion of university commerce and law degrees he worked as an external auditor with a major international chartered accounting firm and has progressed to a range of internal audit, compliance, senior finance, and company secretarial roles with a number of ASX-listed and unlisted public companies and professional services firms, covering financial services, utilities, biotech, IT services, mineral exploration and environmental technologies. He specialises in financial reporting and company secretarial practice.공시 • Jan 28Mach7 Technologies Limited Provides Revenue Guidance for the Year 2023Mach7 Technologies Limited provided revenue guidance for the year 2023. The company expects +20% revenue growth in fiscal year 2023, underpinned by a healthy pipeline and the recognition of revenue from the Trinity Health and Adventist Health sales orders as Mach7's software progressively goes live. Approximately 80-85% of the TCV associated with these contracts is yet to be recognised as revenue. At approximately 70% towards its goal, Mach7 remains confident of achieving its fiscal year 2023 sales order forecast of at least $36 million, which represents a 20% increase on the fiscal year 2022 target of $30 million and +8% on the $33.2 million achieved.매출 및 비용 세부 내역Mach7 Technologies가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:TDMM.F 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2530-107030 Sep 2532-87030 Jun 2534-68031 Mar 2534-68031 Dec 2434-58030 Sep 2431-78030 Jun 2429-87031 Mar 2428-77031 Dec 2327-68030 Sep 2329-37030 Jun 2330-17031 Mar 2329-26031 Dec 2228-45030 Sep 2227-45030 Jun 2226-44031 Mar 2226-34031 Dec 2126-33030 Sep 2123-63030 Jun 2119-93031 Mar 2118-93031 Dec 2017-83030 Sep 2018-43030 Jun 201903031 Mar 2017-12031 Dec 1915-22030 Sep 1912-52030 Jun 199-72031 Mar 199-72031 Dec 188-62030 Sep 188-52030 Jun 189-52031 Mar 189-113031 Dec 179-173030 Sep 1710-173030 Jun 1710-184031 Mar 178-163031 Dec 166-153030 Sep 164-143030 Jun 162-133031 Dec 158-38030 Jun 150-720양질의 수익: TDMM.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: TDMM.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: TDMM.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 4.9% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 TDMM.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: TDMM.F은 수익성이 없어 지난 해 수익 성장률을 Healthcare Services 업계(4.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: TDMM.F는 현재 수익성이 없으므로 자본 수익률이 음수(-25.89%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 11:57종가2026/05/21 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Mach7 Technologies Limited는 8명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Madeleine WilliamsCanaccord GenuityShane StoreyCanaccord GenuityScott PowerCGS International5명의 분석가 더 보기
공시 • Apr 21Mach7 Technologies Limited to Report Q3, 2026 Results on Apr 24, 2026Mach7 Technologies Limited announced that they will report Q3, 2026 results at 4:12 PM, AUS Eastern Standard Time on Apr 24, 2026
공시 • Jan 22Mach7 Technologies Limited to Report Q2, 2026 Results on Jan 30, 2026Mach7 Technologies Limited announced that they will report Q2, 2026 results on Jan 30, 2026
공시 • Oct 23Mach7 Technologies Limited to Report Q1, 2026 Results on Oct 31, 2025Mach7 Technologies Limited announced that they will report Q1, 2026 results on Oct 31, 2025
공시 • Aug 08Mach7 Technologies Limited to Report Fiscal Year 2025 Results on Aug 27, 2025Mach7 Technologies Limited announced that they will report fiscal year 2025 results on Aug 27, 2025
공시 • Apr 14Mach7 Technologies Limited to Report Q3, 2025 Results on Apr 29, 2025Mach7 Technologies Limited announced that they will report Q3, 2025 results on Apr 29, 2025
공시 • Jan 31Mach7 Technologies Limited to Report First Half, 2025 Results on Feb 27, 2025Mach7 Technologies Limited announced that they will report first half, 2025 results on Feb 27, 2025
공시 • Apr 21Mach7 Technologies Limited to Report Q3, 2026 Results on Apr 24, 2026Mach7 Technologies Limited announced that they will report Q3, 2026 results at 4:12 PM, AUS Eastern Standard Time on Apr 24, 2026
공시 • Jan 22Mach7 Technologies Limited to Report Q2, 2026 Results on Jan 30, 2026Mach7 Technologies Limited announced that they will report Q2, 2026 results on Jan 30, 2026
공시 • Oct 23Mach7 Technologies Limited to Report Q1, 2026 Results on Oct 31, 2025Mach7 Technologies Limited announced that they will report Q1, 2026 results on Oct 31, 2025
공시 • Oct 02Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2025Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2025.
공시 • Aug 08Mach7 Technologies Limited to Report Fiscal Year 2025 Results on Aug 27, 2025Mach7 Technologies Limited announced that they will report fiscal year 2025 results on Aug 27, 2025
공시 • Jul 10+ 1 more updateMach7 Technologies Limited Provides Preliminary Unaudited Earnings Guidance for the Year Ended June 30, 2025Mach7 Technologies Limited provides preliminary unaudited earnings guidance for the year ended June 30, 2025. For the period, revenue is expected to finalize at approximately AUD 33 million to AUD 34 million in line with fiscal year 2025 guidance for revenue growth of 15-25% (AUD 33 million to AUD 36 million). This reflected strong growth in recurring revenue of approximately 20%. Contracted Annual Recurring Revenue is expected to finalize at approximately AUD 30 million to AUD 31 million, slightly below fiscal year 2025 guidance for CARR growth of 15-25% (AUD 32 million to AUD 35 million). OPEX growth will be less than revenue growth in line with fiscal year 2025 guidance.
공시 • Apr 14Mach7 Technologies Limited to Report Q3, 2025 Results on Apr 29, 2025Mach7 Technologies Limited announced that they will report Q3, 2025 results on Apr 29, 2025
공시 • Feb 28Mach7 Technologies Announces Product Launch of the Eunity Diagnostic Image Viewer Using Aws HealthimagingMach7 Technologies announced a breakthrough in medical imaging access, performance, and cloud enablement with the release of its eUnity Enterprise Diagnostic Viewer, which uses AWS HealthImaging. The release marks a major milestone for Mach7 in its continuing goal of delivering new, impactful offerings to the Healthcare IT sector. Mach7 is a part of the AWS Partner Network (APN), a global community that leverages programs, expertise, and resources to build, market, and sell customer offerings with smart integration to the cloud. The release is a significant innovation with advanced cloud capabilities that allow clinicians to have fast access to patient studies across the healthcare enterprise regardless of acquisition or data source. Key benefits: One visualization experience with the eUnity Zero Footprint Diagnostic Enterprise Viewer; Leverage High-Throughput JPEG 2000 (HTJ2K) utilized with AWS HealthImaging data stores; Federation of multiple archive locations including local storage and multiple AWS HealthImaging data stores. At petabyte scale, data transfer speeds equal to or exceeding traditional local storage models at petabyte scale, using AWS HealthImaging; Allows full control of data to support customized workflows, clinical research, and artificial intelligence (AI) modeling; The ability to segment studies for various reading groups and practices and build privilege-based access strategies for different user groups; Utilize current reading worklist to leverage current IT investments; All images are available from local or cloud data stores with no sacrifice in performance with full diagnostic image quality at sub-second latency. eUnity, using AWS HealthImaging, creates a powerful diagnostic imaging solution for clinicians and IT staff that enables automated, efficient workflows, vast scalability, and cost savings.
공시 • Jan 31Mach7 Technologies Limited to Report First Half, 2025 Results on Feb 27, 2025Mach7 Technologies Limited announced that they will report first half, 2025 results on Feb 27, 2025
공시 • Jan 30Mach7 Technologies Limited (ASX:M7T) announces an Equity Buyback for 24,124,104 shares, representing 10% for AUD 5 million.Mach7 Technologies Limited (ASX:M7T) announces a share repurchase program. Under the program, the company will repurchase up to 24,124,104 shares, representing 10% of its issued share capital, for AUD 5 million. The shares will be repurchased at the price no more than 5% above the volume weighted average price of company's shares over the five trading days prior to purchase. The shares repurchased will be cancelled. The program is valid till February 3, 2026. As of January 30, 2025, there are 241,241,047 outstanding shares.
공시 • Jan 21Mach7 Technologies Limited to Report Q2, 2025 Results on Jan 31, 2025Mach7 Technologies Limited announced that they will report Q2, 2025 results on Jan 31, 2025
공시 • Nov 12Mach7 Technologies Introduces UnityVue, A Next-Generation Radiology Reading Solution with Groundbreaking CapabilitiesMach7 Technologies announced the formal launch of UnityVue, a landmark radiology software platform developed in partnership with NewVue. UnityVue is a pioneering solution which integrates Mach7's well-renown eUnity Enterprise Diagnostic Viewer (eUnity) with NewVue's revolutionary EmpowerSuite Workflow Orchestrator, delivering a comprehensive software platform designed to improve radiology reading workflows. UnityVue consolidates radiology workflows by seamlessly integrating image viewing and worklist management. This cloud-based solution offers radiologists a powerful platform for task prioritization, AI-driven data aggregation, and enhanced diagnostic workflow—all from a single interface. UnityVue's ability to dynamically curate worklists and automate data normalization enhances productivity while reducing administrative burden. UnityVue's key features include cloud-based image access, real-time AI-driven workflow orchestration, automated data normalization, and a unified interface for radiologists to perform their tasks efficiently. With its zero-footprint design, UnityVue allows radiologists to access critical information from any location, enhancing productivity while reducing administrative complexity. Through the launch of UnityVue, Mach7 customers have a future proof, all-in-one solution that not only meets the current demands of radiologists but also anticipates future needs. By solving these critical challenges, healthcare organizations can deploy a platform that enhances job satisfaction for radiologists, improves patient care, and drives better business outcomes. Key Benefits: For Independent Delivery Networks: Unifying PACS: Integrates multiple PACS systems into a single platform, simplifying workflows and reducing inefficiencies. Gradual Cloud Migration: IDNs can migrate to the cloud incrementally, preserving existing systems while modernizing infrastructure. Disaster Recovery: Cloud-based continuity ensures radiologists can continue working during local system outages. Reduced IT Complexity: The zero-footprint design eliminates on-site server requirements and minimizes maintenance.
공시 • Oct 11Mach7 Technologies Limited to Report Q1, 2025 Results on Oct 31, 2024Mach7 Technologies Limited announced that they will report Q1, 2025 results on Oct 31, 2024
공시 • Oct 03Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2024Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2024.
공시 • Jul 12Mach7 Technologies Limited to Report Fiscal Year 2024 Results on Aug 28, 2024Mach7 Technologies Limited announced that they will report fiscal year 2024 results on Aug 28, 2024
공시 • Jul 10Mach7 Technologies Limited to Report Q4, 2024 Results on Jul 30, 2024Mach7 Technologies Limited announced that they will report Q4, 2024 results on Jul 30, 2024
공시 • Apr 08Mach7 Technologies Limited to Report Q3, 2024 Results on Apr 24, 2024Mach7 Technologies Limited announced that they will report Q3, 2024 results on Apr 24, 2024
공시 • Feb 15Mach7 Technologies Limited to Report First Half, 2024 Results on Feb 29, 2024Mach7 Technologies Limited announced that they will report first half, 2024 results on Feb 29, 2024
공시 • Jan 23Mach7 Technologies Limited to Report Q2, 2024 Results on Jan 31, 2024Mach7 Technologies Limited announced that they will report Q2, 2024 results on Jan 31, 2024
공시 • Nov 18Mach7 Technologies Limited Appoints Rebecca Thompson as DirectorMach7 Technologies Limited announced appointment of Rebecca Thompson as director. Date of appointment is 16 November 2023.
공시 • Oct 23Mach7 Technologies Limited to Report Q1, 2024 Results on Oct 31, 2023Mach7 Technologies Limited announced that they will report Q1, 2024 results on Oct 31, 2023
공시 • Sep 22Mach7 Technologies Limited Announces Board Changes, Effective 16 November 2023Mach7 Technologies Limited announced that Mr. Philippe Houssiau will retire as Non-Executive Director of the company, effective from the close of the Company's Annual General Meeting on 16 November 2023 and that Ms. Rebecca Thompson has agreed to join the Mach7 Board as an independent Non-Executive Director, following the conclusion of the Company's Annual General Meeting on 16 November 2023. Mr. Houssiau joined the Mach7 Board in January 2021 as an independent Non-Executive Director and has served on the Company's Remuneration and Nomination Committee. As a part of the recently announced Board renewal process Ms Thompson will be joining the Board as a Non-Executive Director. Ms Thompson has deep experience in financial markets with senior roles at global investment banks, most recently at J.P. Morgan, and with listed companies over her 30-year career to date. Since mid-2022 and until her recent appointment as head of investor relations at CSR Limited, Rebecca was a consultant to Mach7. Apart from providing Rebecca with a strong understanding of the Mach7 business and its market dynamics, the relationship has demonstrated Rebecca's professionalism, commercial acumen, compatibility and sound judgement. Rebecca's professional experience spans the property, resources, fintech and charitable sectors with a strong focus on sustainability and ESG. She holds a Bachelor Degree in Economics from the University of Sydney and has a graduate qualification in finance and investment.
공시 • Aug 28Mach7 Technologies Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Mach7 Technologies Limited announced that they will report fiscal year 2023 results on Aug 31, 2023
공시 • Aug 11Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023.
공시 • Jul 28Mach7 Technologies Limited to Report Q4, 2023 Results on Jul 31, 2023Mach7 Technologies Limited announced that they will report Q4, 2023 results on Jul 31, 2023
공시 • Feb 01Mach7 Technologies Limited Announces Change of Company SecretaryMach7 Technologies Limited announced the appointment of Mr. Tony Panther as Company Secretary, effective 1 February 2023, to replace Ms. Veronique Morgan-Smith, following team reassignments at Vistra Australia, the Company's provider of secretarial and corporate compliance services. Mr. Panther is a Chartered Accountant with over 30 years' experience in a variety of fields. Following completion of university commerce and law degrees he worked as an external auditor with a major international chartered accounting firm and has progressed to a range of internal audit, compliance, senior finance, and company secretarial roles with a number of ASX-listed and unlisted public companies and professional services firms, covering financial services, utilities, biotech, IT services, mineral exploration and environmental technologies. He specialises in financial reporting and company secretarial practice.
공시 • Jan 28Mach7 Technologies Limited Provides Revenue Guidance for the Year 2023Mach7 Technologies Limited provided revenue guidance for the year 2023. The company expects +20% revenue growth in fiscal year 2023, underpinned by a healthy pipeline and the recognition of revenue from the Trinity Health and Adventist Health sales orders as Mach7's software progressively goes live. Approximately 80-85% of the TCV associated with these contracts is yet to be recognised as revenue. At approximately 70% towards its goal, Mach7 remains confident of achieving its fiscal year 2023 sales order forecast of at least $36 million, which represents a 20% increase on the fiscal year 2022 target of $30 million and +8% on the $33.2 million achieved.